WO2009135614A3 - Use of a virus regimen for the treatment of diseases - Google Patents

Use of a virus regimen for the treatment of diseases Download PDF

Info

Publication number
WO2009135614A3
WO2009135614A3 PCT/EP2009/003074 EP2009003074W WO2009135614A3 WO 2009135614 A3 WO2009135614 A3 WO 2009135614A3 EP 2009003074 W EP2009003074 W EP 2009003074W WO 2009135614 A3 WO2009135614 A3 WO 2009135614A3
Authority
WO
WIPO (PCT)
Prior art keywords
regimen
virus
cell
treatment
diseases
Prior art date
Application number
PCT/EP2009/003074
Other languages
French (fr)
Other versions
WO2009135614A2 (en
Inventor
Werner Krause
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of WO2009135614A2 publication Critical patent/WO2009135614A2/en
Publication of WO2009135614A3 publication Critical patent/WO2009135614A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of a virus regimen, especially an oncolytic regimen for the production of a medicament for the treatment of a disease, especially cancer is decribed. The virus regimen is applied after reducing, shutting down or modifiying functioning of the immune system in a controlled manner. In a preferred embodiment T-cell depletion or T-cell modification is used for controlling the immune system. The T-cell depletor or T-cell modifier is administered either separately or as part of the virotherapy regimen.
PCT/EP2009/003074 2008-05-09 2009-04-28 Use of a virus regimen for the treatment of diseases WO2009135614A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08075487 2008-05-09
EP08075487.2 2008-05-09
US5278008P 2008-05-13 2008-05-13
US61/052.780 2008-05-13

Publications (2)

Publication Number Publication Date
WO2009135614A2 WO2009135614A2 (en) 2009-11-12
WO2009135614A3 true WO2009135614A3 (en) 2010-08-26

Family

ID=41265068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/003074 WO2009135614A2 (en) 2008-05-09 2009-04-28 Use of a virus regimen for the treatment of diseases

Country Status (7)

Country Link
US (1) US20090280122A1 (en)
AR (1) AR071755A1 (en)
PA (1) PA8826101A1 (en)
PE (1) PE20091899A1 (en)
TW (1) TW201004644A (en)
UY (1) UY31819A (en)
WO (1) WO2009135614A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120301506A1 (en) * 2010-11-23 2012-11-29 Xiaoliu Zhang Oncolytic Virus as an Inducer for Innate Antitumor Immunity
CN109328075A (en) * 2016-05-11 2019-02-12 俄亥俄州国家创新基金会 Oncolytic virus comprising esRAGE and the method for treating cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003005964A2 (en) * 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
WO2007093036A1 (en) * 2006-02-13 2007-08-23 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
WO2008011726A1 (en) * 2006-07-27 2008-01-31 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
WO2009052617A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
CA2388807C (en) * 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
MX2008002743A (en) * 2005-08-31 2008-03-26 Oncolytics Biotech Inc Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003005964A2 (en) * 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
WO2007093036A1 (en) * 2006-02-13 2007-08-23 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
WO2008011726A1 (en) * 2006-07-27 2008-01-31 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
WO2009052617A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CESAIRE R ET AL: "Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia", ONCOGENE, vol. 25, no. 3, January 2006 (2006-01-01), pages 349 - 358, XP002557571, ISSN: 0950-9232 *
FREYTAG S ET AL: "83 Clinical trials combining oncolytic viral therapy and suicide gene therapy with conformalradiotherapy", RADIOTHERAPY AND ONCOLOGY, ELSEVIER LNKD- DOI:10.1016/S0167-8140(06)80577-3, vol. 78, 1 March 2006 (2006-03-01), pages S29 - S30, XP025052618, ISSN: 0167-8140, [retrieved on 20060301] *
HAAS CLAUDIA ET AL: "A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 1 FEB 2006 LNKD- PUBMED:16108015, vol. 118, no. 3, 1 February 2006 (2006-02-01), pages 658 - 667, XP002583188, ISSN: 0020-7136 *
HIRASAWA KENSUKE ET AL: "Systemic reovirus therapy of metastatic cancer in immune-competent mice.", CANCER RESEARCH, vol. 63, no. 2, 15 January 2003 (2003-01-15), pages 348 - 353, XP002557570, ISSN: 0008-5472 *
PENACK O ET AL: "Serotherapy with thymoglobulin and alemtuzumab differentially influences frequency and function of natural killer cells after allogeneic stem cell transplantation.", BONE MARROW TRANSPLANTATION FEB 2008 LNKD- PUBMED:17982494, vol. 41, no. 4, February 2008 (2008-02-01), pages 377 - 383, XP002583189, ISSN: 0268-3369 *
RUSSELL ET AL: "Viruses as anticancer drugs", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 28, no. 7, 1 July 2007 (2007-07-01), pages 326 - 333, XP022141554, ISSN: 0165-6147 *
VAHA-KOSKELA ET AL: "Oncolytic viruses in cancer therapy", CANCER LETTERS, NEW YORK, NY, US, vol. 254, no. 2, 8 September 2007 (2007-09-08), pages 178 - 216, XP022182282, ISSN: 0304-3835 *

Also Published As

Publication number Publication date
PE20091899A1 (en) 2010-01-21
PA8826101A1 (en) 2009-12-16
US20090280122A1 (en) 2009-11-12
TW201004644A (en) 2010-02-01
WO2009135614A2 (en) 2009-11-12
UY31819A (en) 2010-01-05
AR071755A1 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
WO2011056688A3 (en) Molecular profiling for personalized medicine
WO2011005595A3 (en) 2-5a analogs and their methods of use
WO2008096831A1 (en) Therapeutic agent for cancer
WO2009149179A3 (en) Enhanced antiviral therapy methods and devices
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX356210B (en) Acrylic polymer formulations.
WO2007081879A3 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
WO2013006569A3 (en) Herpes virus vaccine and methods of use
WO2014182955A3 (en) Targeting the egfr-sglt1 interaction for cancer therapy
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
MX339460B (en) Benzazole derivatives as histamine h4 receptor ligands.
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
WO2011100769A3 (en) Kinase modulators for the treatment of cancer
DK2802319T3 (en) FIXED DOSAGE COMBINATION THERAPY FOR PARKINSON'S DISEASE
WO2009135614A3 (en) Use of a virus regimen for the treatment of diseases
MX2013007055A (en) Sanglifehrin derivatives and methods for their production.
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation
WO2014055941A3 (en) Compounds and methods for targeted immune system delivery
WO2011153819A8 (en) Pharmaceutical composition for treating drug addiction
WO2008096081A3 (en) Use of riluzole and derivatives thereof for producing new drugs
Rotar et al. Clinical contrasts with the American College of Rheumatology/European League Against Rheumatism provisional definitions of remission in rheumatoid arthritis for clinical trials: Comment on the article by Felson et al
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
UA35024U (en) Method for treating adult patients with non-viral hepatitis
WO2009008888A8 (en) African swine virus polypeptides as vaccines and its therapeutic use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09741833

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09741833

Country of ref document: EP

Kind code of ref document: A2